CSG MESO

N/A

Report date: 2023/02/19 23:42:24

Base Information

Drug NameCSG MESO

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesCARsgen Therapeutics Holdings Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCARsgen Therapeutics Holdings Ltd

Active IndicationsN/A

Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A